Kura Oncology at Leerink Conference: Strategic Advances in AML Therapies

On Wednesday, 12 March 2025, Kura Oncology (NASDAQ: KURA) presented at the Leerink Global Healthcare Conference 2025, highlighting its strategic advances in targeted therapies for acute leukemia (AML) and other indications. The company shared both promising developments and challenges, including the anticipated submission of a New Drug Application (NDA) and the financial runway supported by collaborations.

Key Takeaways

• Kura Oncology plans to submit an NDA for zifdomenib in Q2 2025, aiming for approval by year-end.
• The company holds approximately $750 million in cash, with additional $420 million expected from collaborations.
• Zifdomenib’s peak sales in AML are projected at $3 billion, with a total class market of $7 billion in the U.S.
• Two Phase 3 trials in frontline AML are underway, designed for both fit and unfit populations.
• Kura is exploring menin inhibitors for other conditions, including gastrointestinal stromal tumors (GIST) and diabetes.

Financial Results

• Cash Position:

- Kura Oncology ended the year with $750 million in cash and cash equivalents.

- An additional $420 million is anticipated from the Kewakirin collaboration.

• Financial Runway:

- The collaboration with Kewakirin is expected to provide financial stability through 2029, supporting commercialization efforts for zifdomenib in frontline AML.

• Commercial Potential:

- The relapsed/refractory AML market is estimated at $350 million to $400 million.

- Zifdomenib could achieve peak sales of $3 billion in AML, with the overall menin inhibitor class reaching $7 billion in the U.S.

Operational Updates

• NDA Submission:

- Kura plans to submit an NDA for zifdomenib in the second quarter of 2025.

• Phase 3 Trials:

- Two Phase 3 trials are in progress, targeting both fit and unfit AML populations.

• Trial Design:

- The trials include a study for fit patients (zifdomenib vs. placebo) and one for unfit patients (venetoclax azacitidine plus zifdomenib vs. placebo).

• Accelerated Approval:

- The FDA has agreed to minimal residual disease (MRD) negative complete response as an accelerated approval endpoint.

Future Outlook

• Market Position:

- Kura aims to capture a significant share of the AML market, targeting up to half of all patients.

• Timelines:

- Readouts for the MRD negative complete response are expected in 2028.

• Menin Inhibitors Beyond AML:

- Kura is developing menin inhibitors for diabetes and other solid tumors, with a GIST trial starting in the first half of 2025.

• FTI Program Strategy:

- The company is advancing its farnesyltransferase inhibitor program, with data expected later in the year.

Q&A Highlights

• COMET-one Data:

- The primary endpoint was achieved in the COMET-one study for relapsed/refractory NPM1 mutant AML.

• Zifdomenib Combinability:

- The drug shows good combinability with other standard-of-care treatments.

In conclusion, Kura Oncology’s presentation at the Leerink Global Healthcare Conference 2025 showcased its robust pipeline and strategic initiatives in AML and beyond. For more detailed insights, refer to the full transcript below.

Full transcript - Leerink Global Healthcare Conference 2025:

Jonathan Chang, Equity Research Team, Alerink Partners: Good morning, everyone. Thanks for joining us. My name is Jonathan Chang. I’m part of the Alerink Partners Equity Research Team. It’s my pleasure to host the management team of CURA Oncology.

We have with us today President and CEO, Troy Wilson and CMO, Molly Leone. Thank you both for joining us. Let’s get started. Would you like to briefly introduce the company?

Troy Wilson, President and CEO, CURA Oncology: Sure, Jonathan. Thank you. Thanks for the invitation to participate in the conference, and for for hosting this fireside chat. Kura is advancing a pipeline of targeted therapies in oncology. Our lead asset is a menin inhibitor for treatment of acute leukemia.

We are expecting to submit an NDA, a new drug application in the second quarter. Hopefully, that will support an approval around the end of the year, and then we would look to launch that. We have an expansive development program, which I know we’ll talk about. We are undertaking two Phase three trials in the frontline population in AML. Beyond that, we’re looking at other indications in AML as well as menin inhibitors in gastrointestinal stromal tumors trial, which will start later this in the first half of the year, solid tumors in diabetes, as well as our pipeline of farnesyltransferase inhibitors, which are directed at large solid tumors.

The final thing, Jonathan, I’ll share is, we are in a very strong and I think derisked position financially. We had $750,000,000 approximately in cash and cash equivalents as of the end of the year. We are on track to receive an additional $420,000,000 in near term milestones under our collaboration with Kewakirin. That will do two things. It should give us cash into twenty twenty twenty excuse me, 2029 through commercialization of ziptonimab in the frontline AML indications, and it should allow the company to stay in a very strong cash position as we prosecute our pipeline.

Jonathan Chang, Equity Research Team, Alerink Partners: Great. Thank you so much for the introduction. What do you see as the potential opportunity for the menin inhibitor, zifdomenib in AML?

Troy Wilson, President and CEO, CURA Oncology: Yeah. So maybe we can talk clinically and then commercially. In the relapsedrefractory setting, you’re really looking to improve these patients’ quality of life to sustain survival. We would expect durations of treatment of approximately six months. The frontline setting is quite different.

When you treat patients at what we’ve seen with menin inhibitors in the frontline setting, you’re able to do two things. It looks like you’re able to deepen responses. You’re able to extend the duration of responses. And in the case of the NPM1 population, which is about a third of AML, we’re seeing fewer patients needing to go to transplant with all the relapsedrefractory market, our best guess is that’s several hundred million dollars I think we’ve guided to $350,000,000 to 400,000,000. The frontline indication is our best guess is Zifdomenib could drive peak sales in AML of $3,000,000,000 and the total class could drive peak sales in The U.

S. Of approximately $7,000,000,000 And the way we get there is we think menin inhibitors will treat half patients with AML, think about durations of therapy of twelve to twenty four months. And then we’ve seen analog pricing from one of our competitors in the menin space. So it’s a significant studies? Sure.

You want to

Jonathan Chang, Equity Research Team, Alerink Partners: take that? Sure. Yes. So our plan studies. Sure.

Troy Wilson, President and CEO, CURA Oncology: You want to take that?

Molly Leone, CMO, CURA Oncology: Sure. Yeah. So our plan has always been to be able to get our menin inhibitor, zifedaminib, to the broadest patient population, essentially have a spot for anyone that has a menin pathway dependent leukemia. Best way to do that is in the front line. So currently, we have designed our 17 trial and are operationalizing it so that we can start enrolling by end of year.

But it is a trial that essentially contains two studies in one. One for the fit population and one for the unfit population. For the fit population, they can receive seven plus three in conjunction with ziftomedib versus placebo. And in the unfit population, it’s venetoclax azacitidine plus zyftaminib versus placebo. And with that, we hope to be able to obviously treat both the fit and unfit.

And also the seven plus three portion of the study is designed to really focus on being able to keep these patients on their post consolidation maintenance, so post transplant, etcetera, to be able to stay on therapy for very long term.

Jonathan Chang, Equity Research Team, Alerink Partners: Understood. Can you discuss the utilization of minimal residual disease negative complete response as an endpoint in the 17 intensive combination study?

Molly Leone, CMO, CURA Oncology: Sure.

Jonathan Chang, Equity Research Team, Alerink Partners: So And maybe also provide some color on the regulatory interactions around.

Molly Leone, CMO, CURA Oncology: Right. So in designing a trial to get it to your frontline patients, if you go with a normal full approval endpoint, it’s many years in the making before you’re going to be able to get this therapy to patients. So the FDA does have a method called accelerated approval that’ll help you get there, a little faster with an endpoint that they feel is a surrogate for overall survival. To this day, they’ve really only used complete response as that endpoint. With seven plus three, the complete response rate is so high, with the backbone that we had to get creative and come up with something else.

That something else is MRD negative complete response, so minimal residual disease negative complete response. And this is something we proposed to the FDA as an accelerated approval endpoint, And they actually they agreed to the endpoint with obviously the caveats that we provide all the necessary data at the time of submission. So it was a big win for both the patients and for the field in general. And our KOLs are thrilled that now this will help them get drugs to patients much more quickly in the front line.

Jonathan Chang, Equity Research Team, Alerink Partners: Understood. How should we be thinking about timelines associated with the 17 studies?

Molly Leone, CMO, CURA Oncology: So we’ve previously guided that we’ll have that readout for the MRD negative CR in 2028. And then obviously, the full approval will be coming after. We haven’t yet guided towards our venetoclax azacitidine accelerated approval readout or full approval readout.

Jonathan Chang, Equity Research Team, Alerink Partners: Understood. You’ve already touched on the cash position that you have, Troy, earlier in your introductory comments. How would you say the Keyawak here in partnership is helping facilitate your goals with Zifdomenin to be more broadly?

Troy Wilson, President and CEO, CURA Oncology: Yes. No, absolutely. So there’s three aspects to that, Jonathan. The first aspect is our ability to invest in maximizing the value of zifedemaib. The second is what we can do commercially to compete in the marketplace.

And then the third is the pipeline. So as Molly mentioned, not only did she and her team secure these pathways to accelerated approval, but very cleverly put two Phase three trials under a single protocol. That allows us to operationalize that trial once, which is where large pharma companies can run circles around smaller companies. It’s just the site activation, the contracting, the budgeting. They were involved with and supportive of the design, and it’ll really be, you know, we we get operational synergies out of out of running the trial, and we can invest in running these two trials in parallel such that we now have a protocol that’s available to, as Molly said, to nearly anyone in the front line.

That’s a significant investment. Those trials are approximately $200,000,000 to $250,000,000 each. So for a company our size, we can take these on. We can be very competitive with the other competitors in the men in space. The second is we will be we’re working under a co commercialization agreement with Kyok Kirin.

Kyokuren is actually funding half of the commercialization expenses in The US, and we are prepared to compete for every patient. We think we’re going to be very competitive in the space, and we’re going to be out there both promoting on the label and educating about the benefits of menin inhibitors. And then the final piece, Jonathan, and one that’s perhaps overlooked, but I think is important particularly particularly in these, you know, these challenging times in the markets is this partnership allows us to also invest in our pipeline. So, as Zifdomenib and GIST. We think that’s potentially a blockbuster opportunity, pursuing menin inhibitors in both solid tumors and diabetes.

And then as we’ve said, we’re going to show data on our farnesotransferase And then as we’ve said, we’re gonna show data on our farnesyltransferase program, later this year potentially at ESMO. We we would be very challenged to do all of this had we not done the partnership. So it’s allowing us to to really invest for the future, to invest for growth.

Jonathan Chang, Equity Research Team, Alerink Partners: Got it. And how do you see Zifto Minib positioned in the competitive landscape?

Troy Wilson, President and CEO, CURA Oncology: Our hope is, again, we will be a significant segment of the market in up to half of all AML patients across all lines of therapy. Zifto continues to, you know, we, Molly actually said to me very early in the development program, you know, this is a drug that is intended to be used in combination. And people lose sight of that as they watch the evolving monotherapy data. But if you’ve seen our data at ASH, you’ll see our upcoming data potentially at EHA and then later this year at ASH. The clinical benefit just gets better as you go earlier and as you go in combination.

Zifto is so, so active. It’s so tissue penetrant. It’s so well tolerated. We think it really could be the, you know, the premier choice among physicians. It it doesn’t have any of the liabilities of some of its competitors as far as safety and tolerability, and that’s what’s hampered other drugs in the AML space.

It’s not a lack of efficacy. It’s that patients have to either dose reduce or discontinue due to due to challenges with tolerability. We’ve not seen any of that with Zifto. So it’s early days. I mean, we have a lot of work to do, but everything we’re seeing and everything that Kira Kiran is seeing tells us that we need to invest aggressively and compete to try to maximize market share.

Jonathan Chang, Equity Research Team, Alerink Partners: Understood. So earlier this year, you disclosed that the COMET-one registrational study in relapsedrefractory NPM1 mutant AML achieved the primary CRCRH endpoint. When can investors expect to see those results? And how should we be thinking about the upcoming data?

Troy Wilson, President and CEO, CURA Oncology: Yes. So we’ve submitted the data for presentation at a major medical meeting here in The US. If the data is accepted for presentation, you’ll see the titles and then the abstracts. Our hope is that we get you know, a highly visible venue in which to present the data. There may be an opportunity to present the data subsequently at another medical meeting.

We’ll see. But that’s what we’d guide to at this point. And so again, assuming it’s accepted, Jonathan, we’ll be able to speak initially to the abstract and then ultimately to the full data set, hopefully again at ASCO or potentially at EHA.

Jonathan Chang, Equity Research Team, Alerink Partners: Understood. Can you talk about why you I guess, we haven’t seen more details around the top line results from the initial disclosure?

Troy Wilson, President and CEO, CURA Oncology: So the number is the primary endpoint. Everybody wants to know the number, right? Is it and we’ve said it’s 20% to 30%, it’s not on the boundary. And it’s stat sig, it’s there’s no new safety. But when we understand in this environment, people are impatient, the rules of the at least one major international conference are very clear.

If you disclose that, you put yourself at risk. It’s not an absolute, but we have to make a decision. We are a more mature company now. We have an obligation to patients. We have an obligation to physicians.

We are we are potentially in a launch year. It’s either this year or next year, hopefully. We need to get this data out to as high a visibility audience as we possibly can among physicians. We don’t want to put that at risk by disclosing the top line results because your next question will be, well, why is it that number and not some other number? Right?

And then, well, what about this? Well, what did you see? Well, it it it you know, it’s it’s death by a thousand cuts. So understand it was you know, if I had it to do over again, I would have guided, top line results perhaps with data to follow at a major medical meeting. But I think we did the right thing.

We did the right thing. If you do the right thing for patients, we can accept a little bit of short term pain. And we are looking forward to sharing the data and walking people through the full data set. It will be very competitive with what’s out there. Understood.

Jonathan Chang, Equity Research Team, Alerink Partners: I think you mentioned this earlier, but just to clarify, what are the timelines for the NDA submission?

Troy Wilson, President and CEO, CURA Oncology: So we’ve guided to second quarter. So we’re on track to hit that. It’s coming up on us quickly.

Jonathan Chang, Equity Research Team, Alerink Partners: Got it. Now, of course, you also touched on the combination data. This is for the COMET this is the COMET seven study with Phase 1b expansion cohort, evaluating zifedomenab with intensive chemotherapy, the seven plus three, expected in 2Q, I believe, and zifdomenib with venetoclax and azacitidine in the second half. Can you discuss the combineability of zifdomenib with standard of care drugs in AML?

Molly Leone, CMO, CURA Oncology: Yeah. So when you’re looking at a drug and whether or not it’s going to be successful, the first, second, and third thing you should look at is its safety profile and your ability to combine it. Because ultimately, in the oncology space, that’s the most important thing, and that’s the only thing that will allow you to get to the appropriate level of efficacy to really help patients. So, so far, as you’ve seen from some of the data we’ve presented and as you will continue to see, zifedometib remains extremely combinable, very easy to combine. With seven plus three, these patients combine it.

They started on day eight, and then they continue on therapy as they go through the backbone therapy and even complete the backbone therapy. They maintain on it even after they complete their consolidation, be that chemotherapy or a transplant. With the venetoclax and azacitidine, these patients are able to go on therapy, stay on our therapy from day eight continuously, and not have to down reduce the dose of venetoclax due to any drug drug interactions, not have to pause Ziftemetab therapy to allow for count recoveries, actually, the addition of Zifdomenib appears to allow the patients to be able to really dial back the VENASA, which is what physicians really want to do considering, how myelosuppressive therapy can be and trying to get these patients away from the risks of infection and bleeds that they have with venetoclax and azacitidine. So the fact that ziftomedim does not have drug interactions, does not have QTC prolongation, and is very easily administered has made the combinability extremely easy.

Jonathan Chang, Equity Research Team, Alerink Partners: Understood.

Troy Wilson, President and CEO, CURA Oncology: I’m good.

Jonathan Chang, Equity Research Team, Alerink Partners: Can you help set expectations ahead of those combination updates later this year?

Troy Wilson, President and CEO, CURA Oncology: Do you want to do that?

Molly Leone, CMO, CURA Oncology: Sure. For the seven plus three arm, you’ve previously seen it. We were at a hundred percent complete response rate. You know, we can’t hold on to that forever, but expect to see very consistent results. Be looking for, at the time of that data presentation, consistency, patient numbers, duration on treatment, and hopefully, we’ll be able to present some MRD data along with that.

For the venetoclax and azacitidine, this will be the first time we’re showing the frontline combination because previously, we did the dose escalation in relapsed refractory patients. So again, I would similarly point to look at how these patients are obviously doing from a efficacy perspective, but the safety will be extraordinarily important to observe and the duration on treatment will be, I think, of great interest to everyone.

Jonathan Chang, Equity Research Team, Alerink Partners: Understood. Let me check with the audience, see if there are any questions on Zifto and AML before I move on. Alright. So, how are you thinking about the opportunities for menin inhibitors beyond AML?

Troy Wilson, President and CEO, CURA Oncology: So we see an opportunity to, extend the use of zifedomenab, to patients with GIST. There’s very compelling, scientific rationale and preclinical data, supporting synergy between menin inhibition and KIT inhibition in GIST. And you’ll see us start that study here in the first half. The significance of that study is we will be, we will be working in patients who are progressing or have progressed on imatinib looking to restore sensitivity. So you get a real we think, you know, we don’t know.

We haven’t started, but we think a relatively quick proof of concept. And that could lead us then to pursue the combination either in the front line or in the front line and in later lines. It’s been described by the clinicians as highly transformative to the GIST field. And GIST is not a small market. It’s 2,000 to 4,000 patients.

Most of them start on imatinib, stay on for a couple of years. Unfortunately, sixty percent or more develop resistance. That’s what we’re looking to address. Imatinib is the drug of choice among physicians who treat GIST. We’re looking to make it that much better by adding ZIFTO.

Beyond that, Jonathan, there is an opportunity for menin inhibitors in diabetes. We’ve guided to a development candidate around the middle of the year. We’re giving ourselves a little bit of a buffer there because we want to pick the right compound. And we’ll talk more about how we would move that compound forward in clinical development and or in a partnership. And then the final opportunity is and that’s with the second distinct menin inhibitor.

There’s a third distinct menin inhibitor. And we’re doing some early work on menin inhibitors in other solid tumors. And nothing to report yet, but some, again, some compelling preclinical data for IP reasons, safety reasons, pricing reasons, IRA reasons. Our view is you’d likely do that with a different menin inhibitor. And just to one final question that’s attached to that, any zifedomenib is the focus of our collaboration with Curecurene.

So we’re working together in acute leukemia. They have an option to opt in on GIST. The rest of the menin inhibitor research and development activities are outside of collaboration.

Jonathan Chang, Equity Research Team, Alerink Partners: Understood. What is the right menin inhibitor for these other opportunities beyond leukine?

Troy Wilson, President and CEO, CURA Oncology: I think you have to let the data drive you. We so we have been investing heavily in menin inhibitor chemistry for multiple years. We have compounds that, for multiple years. We have compounds that, look, you know, qualitatively look more like revumeneb, look more like zifdomenib in terms of their PK profiles, their drug like properties. Do they accumulate in certain tissues?

Are they menin degraders versus simply menin inhibitors? Francis Burrows, our our chief scientific officer, and his team could essentially offer you any flavor you’d like. And so let the data, let the preclinical and ultimately the clinical data be your guide. Zifto or or I think Francis says, Zifto hits men in about as hard as it can be hit. You may not need to hit it that hard for something like diabetes.

You may just actually want to to dial it down, but not actually erase it the way that Zifto does. It’s very potent in the preclinical models, but you may not need to do that. We’ll have the option now of actually assessing that both preclinically and potentially clinically, which is where you wanna be.

Jonathan Chang, Equity Research Team, Alerink Partners: Understood. And what are the timelines for these opportunities for men and beyond leukemias?

Troy Wilson, President and CEO, CURA Oncology: So we’ve guided again development candidate in diabetes, sort of middle of the year. Once that moves into the clinic, think approximately twelve months, you know, for an IND. Too early to talk about menin inhibitors and other solid tumors. I think when we get closer to nominating a development candidate there, we have so many opportunities now that we for which we can create value that we need to be very thoughtful about undertaking clinical development. So we do an extensive amount of preclinical work and now increasingly competitive analysis, development analysis, commercial analysis.

That’s why we see an opportunity in GIST. Other solid tumors, we see opportunities, but we just have more work to be done.

Jonathan Chang, Equity Research Team, Alerink Partners: Understood. Maybe switching over to the farnasol transferase inhibitor efforts. Can you discuss the opportunities for FTIs and solid tumors?

Troy Wilson, President and CEO, CURA Oncology: Yes. So very simply, we’re looking with our FTI program to work in combination to make targeted therapies more effective by addressing innate and adaptive resistance. This has been, you know, this is our understanding of farnesyltransferase has evolved over the last number of years. What we understand is that when you treat a tumor with a TKI or a KRAS inhibitor or an EGFR inhibitor or PI3 kinase inhibitor, the tumor cells respond. They in some cases, they’ll mutate.

They’ll upregulate certain signaling pathways. Those tumor cells, when they are trying to work around a targeted therapy, they invoke pathways that are farnesylation dependent. So while a farnesyltransferase inhibitor might not be effective as a monotherapy, it’s highly effective in preclinical models at blocking innate and adaptive resistance. And that’s probably its highest best use. Right?

Now I’m not going to say it’s the panacea. You can’t use it everywhere. But we have four cohorts across two different trials. So we have our current HN trial, which is evaluating tipifarnib and dalpelosib in PIK3CA 3CA mutant head and neck. And then we have three cohorts in the FIT one trial.

We’ve pledged to show you three of those four, and that’s driven by enrollment, really. The current HN trial, we know that alpelasib delivers at best stable disease. Tipifarnib is dead as a doornail in that population. So if you see responses that are meaningful and durable, that’s telling you you’re seeing target synergy. In the case of the monotherapy, you’re really looking at activity in RAS mutant patients.

Are you going to see tumor shrinkage or responses in HRAS mutant patients? What is the safety and tolerability look like. And then in RCC, a lot of excitement around HIF2 alpha and what that offers. Again, if you look at our preclinical data, there’s some very interesting synergy between cabozantinib, for example, and other TKIs in RCC and FTIs. We’ll spend more time, Jonathan, in the second half of the year educating analysts and investors about how to think about the science, the preclinical data, how to evaluate the clinical data, but that gives you a taste.

The one cohort I left out is KRAS. That’s just enrolling a little bit more slowly, but it’s actually beginning now to gain some momentum. We have put a stake in the ground. We intend to submit the data for a medical presentation in the second half, potentially at ESMO. And so we’ll look to do some education in advance of that so that people can think about it.

As with menin, with FTIs, we have a stable of FTIs. So two thousand eight hundred and six is the is the lead new compound. It’s really a very, very, very, very compelling compound. But again, for a variety of commercial reasons, one may want to take different FTIs off into different directions. We’ll have the ability to do that.

Jonathan Chang, Equity Research Team, Alerink Partners: What what would you say are the are there lessons from the tipifarnib experience that apply to the next generation FTIs?

Troy Wilson, President and CEO, CURA Oncology: Yeah. I think the lessons are so we can use the the monotherapy activity that we saw with TIPI to very rapidly determine the dose. Right? Because it’s HRAS mutant solid tumors are the unique case where when you see tumor shrinkage, you know you’re over the zone. And when you see myelosuppression, you know you’ve gone too high.

That’s a relatively niche population, but it allows you to zero in on on the dose quickly. That’s why this this FIT one protocol is so innovative because we could go very quickly into combinations. Combinations are where it’s at, Jonathan, for a couple of reasons. Resistance is a problem across all drugs in oncology, and you’re now talking about large solid tumor opportunities. So KRAS alone, lung, colorectal, pancreatic, PI3 kinase, you’ve got a range of opportunities.

RCC, second line and potentially first line are significant. I think the learnings are stay the target’s compelling. You have to figure out how to use the biology. What we were missing was the recognition that we actually needed to do it in combination with other targeted therapies. And and I think that’s when it all kind of clicked and fell into place.

And and with, you know, all of the preclinical data is available on our website. People can go and review it. We’re looking to do we’re looking to recapitulate that in the clinic. Right? If we can see that in in these are dose escalation studies, so it’s early days.

But if you see evidence of overcoming resistance to these targeted therapies, that tells you you’re in the right place. And as Molly was saying, the interesting thing that ties the two platforms together is safety, tolerability, and combinability. FTIs are unusual, when we consider other targets like SHIP2, SARS1, and that they are so well tolerated. So if you can get that biology, but while at the same time maintaining really good tolerability, keeping patients on for long periods of time, that’s the ticket.

Jonathan Chang, Equity Research Team, Alerink Partners: Understood. Maybe just in our remaining minutes, catalysts and milestones for this year, what should

Troy Wilson, President and CEO, CURA Oncology: obviously, the monotherapy data is up. So NDA submission, monotherapy data, combination data from common seven likely in the middle of the year, starting the GIST trial. That will go relatively quickly. We think enrollment will go relatively quickly. Shifting to the second half, you’ll have obviously data from the FTIs, as we talked about.

You’ll have additional data from Comet seven. Hopefully, we’ll have a PDUFA and be able to actually transition into a launch. And I think I’ve hit all of them in 2025. It’s a busy year. There’s a lot going on.

Jonathan Chang, Equity Research Team, Alerink Partners: All right. Well, thank you very much for joining us.

Troy Wilson, President and CEO, CURA Oncology: Our pleasure. Thank you.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.